eligibility_summary
Eligibility: ECOG ≤1, histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube cancer (WHO 2020), recurrent/refractory, CA‑125 ≥2×ULN by 510(k)-cleared test, ≥1 measurable lesion (RECIST 1.1), expected survival ≥3 months. Exclude: inadequate cardiac/renal/hepatic function, ALC <100, recent ≥Grade 2 bleed/coagulopathy, significant CNS disease, autoimmune disease needing systemic immunosuppression within 2 years, prior cell/gene therapy. Other criteria apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 1a/1b dose escalation/expansion in recurrent/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer. Interventions: 27T51 anti‑MUC16 CAR T cells (autologous, genetically engineered T‑cell therapy) given IV alone or with cemiplimab and/or bevacizumab. Mechanisms: 27T51 CAR T cells bind MUC16 on tumor cells to trigger T‑cell activation and cytotoxic killing, cemiplimab is a PD‑1–blocking monoclonal antibody that releases checkpoint inhibition to boost antitumor T‑cell function, bevacizumab is an anti‑VEGF‑A monoclonal antibody that inhibits angiogenesis and may improve immune infiltration. Targets/cells/pathways: MUC16‑positive tumor cells, T‑cell PD‑1/PD‑L1 axis, VEGF/VEGFR signaling and tumor vasculature/microenvironment. Primary focus: safety and preliminary activity.